X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Pfizer Fact Sheet, Pfizer Financial Results - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Pfizer Fact Sheet   (PFIZ)

Here is the latest financial fact sheet of Pfizer. For more details, see the Pfizer quarterly results and Pfizer share price and chart. For a sector overview, read our pharmaceuticals sector report.

PFIZER Price History

Price Rs 2,571.1
Mkt Cap Rs m 117,628
Vol '000 1.2
P/E X 32.7
P/CF X 29.4
EPS (TTM) Rs 78.7
% ch % 0.8
No. of shares m 45.75
% ch week % 1.5
% ch 1-mth % -1.0
% ch 12-mth % 43.0
52 week H/L Rs 2,670.0/1,701.0
(As on Jul 18, 2018 (Close))
* Results Consolidated
Excel EXPORT | DO YOU LIKE THESE FACTSHEETS? TELL US!

PFIZER Financials

No. of Mths
Year Ending
12
Mar-13
12
Mar-14
12
Mar-15
12
Mar-16
12
Mar-17
5-Yr Chart
Click to enlarge
PFIZER EQUITY SHARE DATA
High Rs1,4101,7792,3252,7242,055 
Low Rs9999851,1751,6111,651 
Sales per share (Unadj.) Rs351.5372.6405.1439.9429.8 
Earnings per share (Unadj.) Rs168.674.015.366.773.6 
Diluted earnings per shareRs110.048.315.366.773.6 
Cash flow per share (Unadj.) Rs171.376.743.979.387.4 
Dividends per share (Unadj.) Rs32.50360.0012.5015.0020.00 
Adj. dividends per shareRs21.20234.8112.5015.0020.00 
Dividend yield (eoy) %2.726.00.70.71.1 
Book value per share (Unadj.) Rs567.8220.6420.0472.9528.7 
Adj. book value per shareRs370.4143.9420.0472.9528.7 
Shares outstanding (eoy) m29.8429.8445.7545.7545.75 
Bonus/Rights/Conversions  --A-- 
Price / Sales ratio x3.43.74.34.94.3 
Avg P/E ratio x7.118.7114.732.525.2 
P/CF ratio (eoy) x7.018.039.927.321.2 
Price / Book Value ratio x2.16.34.24.63.5 
Dividend payout %19.3486.481.922.527.2 
Avg Mkt Cap Rs m35,93641,23980,06399,16384,777 
No. of employees `0002.82.4NA2.92.8 
Total wages/salary Rs m2,1111,9182,3642,7733,039 
Avg. sales/employee Rs Th3,752.64,600.0NM6,965.56,925.9 
Avg. wages/employee Rs Th755.3793.4NM960.01,070.4 
Avg. net profit/employee Rs Th1,800.4913.8NM1,055.71,186.3 
PFIZER INCOME DATA
Net Sales Rs m10,48811,11818,53320,12319,663 
Other income Rs m1,0521,0946748701,012 
Total revenues Rs m11,54112,21219,20720,99320,674 
Gross profit Rs m1,8272,3853,8304,3203,491 
Depreciation Rs m80801,311579629 
Interest Rs m248510 
Profit before tax Rs m2,7973,3963,1854,6053,864 
Minority Interest Rs m00000 
Prior Period Items Rs m00000 
Extraordinary Inc (Exp) Rs m4,1410-1,110991,304 
Tax Rs m1,9061,1871,3771,6541,801 
Profit after tax Rs m5,0322,2096983,0503,368 
Gross profit margin %17.421.520.721.517.8 
Effective tax rate %68.135.043.235.946.6 
Net profit margin %48.019.93.815.217.1 
PFIZER BALANCE SHEET DATA
Current assets Rs m18,0446,86012,50616,32520,789 
Current liabilities Rs m3,5093,0345,3966,5847,870 
Net working cap to sales %138.634.438.448.465.7 
Current ratio x5.12.32.32.52.6 
Inventory Days Days5750766560 
Debtors Days Days4957322622 
Net fixed assets Rs m2592329,9969,6469,175 
Share capital Rs m298298458458458 
"Free" reserves Rs m16,6466,28618,75821,17823,731 
Net worth Rs m16,9446,58419,21521,63524,189 
Long term debt Rs m00252525 
Total assets Rs m20,5959,76725,43428,88132,706 
Interest coverage x1,166.2944.3414.6886.7403.5 
Debt to equity ratio x00000 
Sales to assets ratio x0.51.10.70.70.6 
Return on assets %24.422.72.810.610.3 
Return on equity %29.733.53.614.113.9 
Return on capital %41.051.610.821.721.4 
Exports to sales %0.100.10.10 
Imports to sales %8.99.423.117.50 
Exports (fob) Rs m1259120 
Imports (cif) Rs m9321,0504,2743,5260 
Fx inflow Rs m155831175263 
Fx outflow Rs m1,2659,4314,3831404,067 
Net fx Rs m-1,110-9,348-4,266-88-4,004 
PFIZER CASH FLOW
From Operations Rs m -160 1,325 1,135 3,455 3,288 
From Investments Rs m 6,259 1,027 -888 -7,009 -2,496 
From Financial Activity Rs m -432 -13,602 -14 -619 -826 
Net Cashflow Rs m 5,667 -11,251 233 -4,174 -35 
* Results Consolidated
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Share Holding

Indian Promoters 0.0%
Foreign collaborators 63.9%
Indian inst/Mut Fund 7.5%
FIIs 4.9%
ADR/GDR 0.0%
Free float 23.7%
Shareholders 85,207
Pledged promoter(s) holding 0.0%
 

Company Information

REGD OFF Pfizer Centre, Patel Estate, S. V. Road, Jogeshwari (W), Mumbai - 400 102
E-MAIL prajeet.nair@pfizer.com WEB www.pfizerindia.com
TELEPHONE (022) 6693 2000 FAX (022) 2678 4569
SECTOR PHARMACEUTICALS GROUP M N C
TR AGENT Karvy Computershare, 17-24, Vithalrao Nagar, Madhapur, Hyderabad-81
AUDITOR B S R & Co. LLP
CHM: R. A. Shah COMP SEC: Prajeet Nair YEAR OF INC: 1950 BSE CODE: 500680 FV (Rs): 10 DIV YIELD (%): 0.8

More Pharmaceuticals Company Fact Sheets:   LUPIN LTD  INDOCO REMEDIES  DISHMAN PHARMA  PANACEA BIOTECH  GSK PHARMA  

Compare PFIZER With:   LUPIN LTD  INDOCO REMEDIES  DISHMAN PHARMA  PANACEA BIOTECH  GSK PHARMA  

Compare PFIZER With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends Lower; Tata Steel & Vedanta Top Losers(Closing)

Indian share markets erased early gains to end lower today, as the opposition parties tabled a no-confidence motion against Prime Minister Narendra Modi's government.

Views on news

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

How to Avoid a 90% Loss Suffered by This Super Investor(The 5 Minute Wrapup)

Jul 12, 2018

Blindly following super investors is a dangerous game to play. Here's how you can avoid such mistakes.

The Answer to Your Wealth Worries: Small Caps (Especially Now)(Profit Hunter)

Jul 10, 2018

If you're worried about the markets - you are on the wrong track. This is opportunity - put your wealth-building hat on, instead - Richa shows you how...

The Multiple Problems with the Minimum Support Price (MSP) System(Vivek Kaul's Diary)

Jul 11, 2018

The price signals that MSP sends out, creates its own set of problems.

New Fund Offer - ICICI Prudential Pharma Healthcare and Diagnostics Fund - Should You Invest?(Outside View)

Jul 6, 2018

ICICI AMC launches an open -ended equity fund following Pharma, Healthcare, Diagnostic and allied theme.

When Disappointment Panda is Around. Buy Quality Stock like This!(Chart Of The Day)

Jul 6, 2018

Buy Companies that can fight all kinds of Pandas and Bears in the long run.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

TRACK PFIZER

MORE ON PFIZER

PFIZER - PANACEA BIOTECH COMPARISON

COMPARE PFIZER WITH

MARKET STATS